Showing results (71-80 of 88) with videos related to
Sort By:
Pageof 9
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2024
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel DiseaseBruce E Sands, Julian Panés, Brian G Feagan, et al.Rheumatology and Therapy|February 22, 2024
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic ArthritisJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.Arthritis and Rheumatism|August 1, 2009
Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximabJürgen Braun, Désirée van der Heijde, Mittie K Doyle, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized studyAlexa B Kimball, Maurizio Podda, Afsaneh Alavi, et al.The Patient|June 29, 2022
Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 StudyAna-Maria Orbai, Laura C Coates, Atul Deodhar, et al.Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.Arthritis and Rheumatism|March 2, 2006
Infliximab treatment maintains employability in patients with early rheumatoid arthritisJosef S Smolen, Chenglong Han, Désirée van der Heijde, et al.Advances in Therapy|August 10, 2022
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 TrialJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.Biochemical and Biophysical Research Communications|June 13, 2021
Hypomethylation-driven overexpression of HJURP promotes progression of hepatocellular carcinoma and is associated with poor prognosisYe Li, Qing Yi, Xiaoli Liao, et al.Arthritis and Rheumatism|March 2, 2006
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trialJosef S Smolen, Désirée M F M Van Der Heijde, E William St Clair, et al.Pageof 9